Aclaris halves headcount, banks on next mid-stage readout after clinical setbacks tanked shares
A month after revealing that its lead candidate had hit a dead end in inflammatory diseases, Aclaris Therapeutics will cut just under half of its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
